Joseph R. Slaughter

Joseph R. Slaughter

Auto-generated profile, based on publicly available information

Joseph R. Slaughter

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
BBBrandon J. Burbach
Brandon J. Burbach
SOStephen D. O’fLanagan
Stephen D. O’fLanagan
QSQi Shao
Qi Shao
KYKatharine M. Young
Katharine M. Young
JSJoseph R. Slaughter
Joseph R. Slaughter
YSYoji Shimizu
Yoji Shimizu
Memory CD8+ T cells populate non-lymphoid tissues (NLTs) following pathogen infection, but little is known about the establishment of endogenous tumor-specific tissue-resident memory T cells (TRM) during cancer immunotherapy. Using a transplantable mouse model of prostate carcinoma, here we report that tumor challenge leads to expansion of naïve neoantigen-specific CD8+ T cells and formation of a small population of non-recirculating TRM in several NLTs. Primary tumor destruction by irreversible electroporation (IRE), followed by anti-CTLA-4 immune checkpoint inhibitor (ICI), promotes robust expansion of tumor-specific CD8+ T cells in blood, tumor, and NLTs. Parabiosis studies confirm that TRM establishment following dual therapy is associated with tumor remission in a subset of cases and protection from subsequent tumor challenge. Addition of anti-PD-1 following dual IRE + anti-CTLA-4 treatment blocks tumor growth in non-responsive cases. This work indicates that focal tumor destruction using IRE combined with ICI is a potent in situ tumor vaccination strategy that generates protective tumor-specific TRM.